Microneedle injection for retinal artery blockage
Part of Eyes & vision, Heart & circulation clinical trials.
This trial tests a tiny needle injection into the artery to dissolve a blockage in the eye's main blood supply. It may help restore vision if the blockage happened within the past week.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have a new blockage in a main artery of your eye (central or branch) that started within the last 7 days.
- Your vision in the affected eye is worse than 20/40 (decimal less than 0.5).
- You do not have a bleeding disorder, uncontrolled high blood pressure, or a recent stroke.
- You are not pregnant or breastfeeding.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new eye injection (GenSci148) for people with wet age-related macular degeneration, diabetic macular edema, or retinal vein occlusion. The injection may help reduce swelling and abnormal blood vessel growth in the retina, which can improve or stabilise vision.
This trial tests whether a specific eye surgery plus targeted clot-busting medicine and gas can improve vision after bleeding under the retina from “wet” age-related macular degeneration. It aims to reduce how long the bleeding lasts and help protect the central vision.
This trial tests if adding mecobalamin (a form of vitamin B12) to standard anti-VEGF eye injections helps people with vision loss caused by a blocked vein in the retina. You must have swelling in the back of the eye and have had no prior treatments for this condition.
This trial tests a new medicine called SMO1 for people with vision loss and swelling in the eye caused by a blocked vein in the retina. It involves regular eye injections to see if the medicine can reduce swelling and improve vision.
This trial tests an eye injection called OLN324 for diabetic macular edema, a condition where fluid builds up in the retina and blurs vision. The treatment aims to improve vision and reduce swelling in the eye.
This trial tests a new medicine called VIS-101, given as an injection into the eye, for people with wet age-related macular degeneration (AMD) who have not been treated before. The goal is to see if it can reduce fluid buildup and improve vision while being safe.
Hear when a new Central Retinal Artery Occlusion trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.